Literature DB >> 15894926

Expression of CDX2, cytokeratins 7 and 20 in sinonasal intestinal-type adenocarcinoma.

José A Ortiz-Rey1, Carlos Alvarez, Pilar San Miguel, Begoña Iglesias, Iosu Antón.   

Abstract

CDX2 is a transcription factor expressed by intestinal epithelium. It is considered as a sensitive marker for a colorectal or-less frequently-gastric origin of adenocarcinomas. The pattern of coordinated expression of cytokeratin (CK) 7 and CK20 is also useful for the diagnosis of the origin of metastatic adenocarcinomas. Expression of CDX2, CK7 and CK20 was investigated in 14 cases of sinonasal intestinal-type adenocarcinoma (SIA), a particular tumor with an enteric-cell-type appearance. Formalin-fixed, paraffin embedded tissue sections were immunostained with monoclonal antibodies using the biotin-labeled streptavidin technique. All of the cases expressed CDX2, being stained 50 to 100% of the tumor cells (mean: 87.2%). CK7 positivity was detected in 8 cases (57.1%), with the staining of 10 to 100% of cells (mean: 65.6%), and CK20 was found in all the tumors (10 to 100% of cells; mean: 78.8%). The histologic resemblance between SIA and colorectal adenocarcinoma is reinforced by the expression of CDX2 and CK20, which are virtually constant in both neoplasms. CDX2 seems to be a marker for cellular phenotype better than an indicator of the origin of adenocarcinomas. CK7 is expressed in SIA less frequently than in colonic adenocarcinoma, but with a rate similar to the subset of rectal tumors, making the differential diagnosis between the two neoplasms difficult.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15894926     DOI: 10.1097/01.pai.0000133058.00588.15

Source DB:  PubMed          Journal:  Appl Immunohistochem Mol Morphol        ISSN: 1533-4058


  8 in total

Review 1.  Immunohistochemical Biomarkers of Gastrointestinal, Pancreatic, Pulmonary, and Thymic Neuroendocrine Neoplasms.

Authors:  Silvia Uccella; Stefano La Rosa; Marco Volante; Mauro Papotti
Journal:  Endocr Pathol       Date:  2018-06       Impact factor: 3.943

2.  Biphasic low-grade nasopharyngeal papillary adenocarcinoma with a prominent spindle cell component: report of a case localized to the posterior nasal septum.

Authors:  Fredrik Petersson; Brendan Pang; David Loke; Li Hao; Benedict Yan
Journal:  Head Neck Pathol       Date:  2011-03-20

3.  Rectal metastasis from lobular breast carcinoma 15 years after primary diagnosis.

Authors:  Maite López Deogracias; Laura Flores Jaime; Iñaki Arias-Camisón; Ilde Zamacola; Jesús Murillo Guibert; Rosa Suescun García; Juan Querejeta Usabiaga; Francisco Martínez García
Journal:  Clin Transl Oncol       Date:  2010-02       Impact factor: 3.405

4.  Among sinonasal tumors, CDX-2 immunoexpression is not restricted to intestinal-type adenocarcinomas.

Authors:  Matthew P Tilson; Gary L Gallia; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2013-07-12

5.  The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: cytokeratin 7-/20+ phenotype is more specific than CDX2 antibody.

Authors:  Reyhan Bayrak; Hacer Haltas; Sibel Yenidunya
Journal:  Diagn Pathol       Date:  2012-01-23       Impact factor: 2.644

Review 6.  Clinicopathological Features of Low-Grade Thyroid-like Nasopharyngeal Papillary Adenocarcinoma.

Authors:  Minhua Li; Jiangguo Wei; Xiaofei Yao; Cheng Wang
Journal:  Cancer Res Treat       Date:  2016-07-04       Impact factor: 4.679

Review 7.  Primary thyroid-like low-grade nasopharyngeal papillary adenocarcinoma: A case report and literature review.

Authors:  Wan-Lin Zhang; Shuang Ma; Lauren Havrilla; Lin Cai; Cheng-Qian Yu; Shuai Shen; Hong-Tao Xu; Liang Wang; Juan-Han Yu; Xu-Yong Lin; Endi Wang; Lian-He Yang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

8.  The Relationship Between Cytokeratins 7 and 20 Expression, and Prognostic Factors in Colon Adenocarcinoma: An Immunohistochemical Study.

Authors:  Mohammad Hossein Gheini; Noushin Jalayer Naderi
Journal:  Iran J Pathol       Date:  2017-04-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.